Shanghai Henlius Biotech, Inc.
About Shanghai Henlius Biotech, Inc.
Categories
-
CN
-
2019On CPHI since
Products from Shanghai Henlius Biotech, Inc. (1)
-
Product 汉利康® (pronounced as Han-Li-Kang) Rituximab Injection
汉利康® (pronounced as Han-Li-Kang) Rituximab Injection. It is the first-ever China-manufactured biosimilar approved by the NMPA for the treatment of non-Hodgkin lymphoma (NHL). Meanwhile, we are also conducting a Phase 3 clinical trial for rheumatoid arthritis (RA) for HLX01 in China. ...
Shanghai Henlius Biotech, Inc. Resources (1)
-
Brochure Henlius Differentiation Highlights & Comprehensive/Diversified mAb Pipeline
Henlius Differentiation Highlights & Comprehensive/Diversified mAb Pipeline
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance